Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.

MLA

Joseph, Nisha S., et al. “Quadruplet Therapy for Newly Diagnosed Myeloma: Comparative Analysis of Sequential Cohorts with Triplet Therapy Lenalidomide, Bortezomib and Dexamethasone (RVd) versus Daratumamab with RVD (DRVd) in Transplant-Eligible Patients.” Blood Cancer Journal, vol. 14, no. 1, Sept. 2024, p. 159. EBSCOhost, https://doi.org/10.1038/s41408-024-01120-9.

APA

Joseph, N. S., Kaufman, J. L., Gupta, V. A., Hofmeister, C. C., Dhodapkar, M. V., Boise, L. H., DiCamillo, S. M., Roberts, D., Nooka, A. K., & Lonial, S. (2024). Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients. Blood Cancer Journal, 14(1), 159. https://doi.org/10.1038/s41408-024-01120-9

Chicago

Joseph, Nisha S, Jonathan L Kaufman, Vilas A Gupta, Craig C Hofmeister, Madhav V Dhodapkar, Lawrence H Boise, Sara M DiCamillo, Danielle Roberts, Ajay K Nooka, and Sagar Lonial. 2024. “Quadruplet Therapy for Newly Diagnosed Myeloma: Comparative Analysis of Sequential Cohorts with Triplet Therapy Lenalidomide, Bortezomib and Dexamethasone (RVd) versus Daratumamab with RVD (DRVd) in Transplant-Eligible Patients.” Blood Cancer Journal 14 (1): 159. doi:10.1038/s41408-024-01120-9.